NZOZ Lecznica Mak Med s.c. — Clinical Trial Site

27 Registered trials

6 Currently recruiting

Organisation

NZOZ Lecznica Mak Med s.c.

Location

Nadarzyn, Poland

Identifier

ORG-100046189

Address

Ul. Wisniowa 22, 05-830, Poland

Departments

40483: NZOZ Lecznica MAK-MED S.C.
N/A
n/d
NA
Nie dotyczy
No Department
Non-public Health Care Center MAK-MED
Not applicable
NZOZ Lecznica MAK-MED s.c.
NZOZ Lecznica MAK-MED. S.C.
reumathology
Rheumatology

Clinical trials at this site (27)

Search interface

A phase III, randomised, double-blind, multicentre study comparing the efficacy, safety, and immunogenicity of proposed tocilizumab biosimil… Not authorised

2022-501361-44-00 Adult patients of either gender with active moderate to 5
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P… Pending

2025-522471-28-00 psoriatic arthritis (PsA) 5
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety … Recruiting

2024-520098-12-00 Cutaneous Lupus Erythematosus 4 2026-02-16
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus E… Recruiting

2025-523552-31-00 Systemic Lupus Erythematosus 5 2026-05-07
A study to learn about the effectiveness and safety of different doses of JNJ-88545223 in people with active psoriatic arthritis Recruiting

2025-523141-10-00 Active Psoriatic Arthritis 4 2026-03-20
A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-experienced Participants with Active Psoriatic Arthritis Recruiting

2024-517284-23-00 Active Psoriatic Arthritis 5 2025-04-23
A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-t… Recruiting

2024-512496-12-00 Moderate to Severe Plaque Psoriasis 5 2025-04-01
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in partici… Recruiting

2024-516219-25-00 psoriatic arthritis 5 2025-03-25
A Phase 2b to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With ACPA-Positive Rheumatoid Arthritis Ended

2024-515973-82-00 ACPA-Positive Rheumatoid Arthritis 4 2025-06-23
A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Efficacy and Safety of CT-P55 with Cosentyx in Patients with Moderat… Ended

2024-513348-27-00 Plaque psoriasis 5 2025-05-09
A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-naïve Participants with Active Psoriatic Arthritis Ended

2023-509239-19-00 Active Psoriatic Arthritis 5 2025-04-03
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active… Ended

2024-516213-20-00 Psoriatic arthritis 5 2025-03-25
A study to learn how well bimekizumab works and how safe it is in adults with psoriatic arthritis Ended

2024-511738-11-00 Psoriatic arthritis 5 2024-12-18
Phase 2 Placebo-controlled Study to Assess the Safety, Efficacy, and PK of ESK-001 in SLE Ended

2022-502105-15-00 Systemic lupus erythematosus 4 2023-10-20
Guselkumab versus Placebo for the Treatment of Active Psoriatic Arthritis in Participants with Inadequate Response and/or Intolerance to One… Ended

2023-504715-33-00 Psoriatic Arthritis 5 2021-09-27
Guselkumab versus Placebo for the Treatment of Psoriatic Arthritis Axial Disease in Bio-naive Participants Ended

2023-504716-15-00 Psoriatic Arthritis 6 2021-08-06
A Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in … Ended

2024-510945-32-00 Rheumatoid arthritis 5 2024-12-17
A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP118… Ended

2024-514981-37-00 Rheumatoid Arthritis 4 2024-12-05
A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) wi… Ended

2023-506664-14-00 Rheumatoid Arthritis 5 2024-10-24
A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis Ended

2023-505841-22-00 Moderate to Severe Plaque Psoriasis 5 2024-04-04
A Phase 1b Study of Imvotamab in Severe Systemic Lupus Erythematosus Ended

2023-506499-29-00 Systemic Lupus Erythematosus 3 2024-02-28
A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of concept Study Evaluating the Efficacy and Safety of Nipocalimab and Cer… Ended

2023-504045-31-00 Rheumatoid Arthritis 4 2024-02-08
A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis Ended

2023-505127-31-00 Rheumatoid Arthritis 3 2024-02-08
Tofacitinib in early active axial spondyloarthritis: a prospective, randomized, double-blind, placebo-controlled multicentre study - FASTLAN… Ended

2023-505050-18-00 Axial spondyloarthritis 6 2023-11-16